Paratek Pharmaceuticals — Transcept Pharmaceuticals — Technical Presentation (April 2010)
23 slides from Paratek Pharmaceuticals's technical presentation, Apr 8, 2010
Slide 1: Intermezzo Clinical data slide supplement
Intermezzo ® Clinical data slide supplement Clinical data slide supplement April 8, 2010 Exhibit 99.1
Slide 2: Important note to readers
Important note to readers Important note to readers The information in this presentation is provided for informational purposes only. The clinical results and other information included in this presentation should not in any way be construed as predictive of the outcome of any future studies, includ
Slide 3: Phase 1 Pharmacokinetic (PK) / Pharmacodynamic (PD) study (2005)
Phase 1 Pharmacokinetic (PK) / Pharmacodynamic (PD) study (2005) Phase 1 Pharmacokinetic (PK) / Pharmacodynamic (PD) study (2005)
Slide 4: Phase 1 PK/PD study (2005)
: Phase 1 PK/PD study (2005) : Phase 1 PK/PD study (2005) Study design: Double-blind, placebo-controlled, daytime, crossover study of 1.0 mg, 1.75 mg and 3.5 mg sublingual zolpidem tartrate tablet in 24 healthy adults (only 1.75 mg and 3.5 mg data shown) Pharmacokinetic assessment: Blood was collect
Slide 5: 3.5 mg and 1.75 mg plasma concentration profile
3.5 mg and 1.75 mg plasma concentration profile 3.5 mg and 1.75 mg plasma concentration profile 3.5 mg 1.75 mg Phase 1 PK/PD Study n=24 Tmax 30-40 min Time (min)
Slide 6: Mean DSST scores change from baseline
: mean DSST scores ( from baseline) : mean DSST scores ( from baseline) Placebo 1.75 mg 3.5 mg Phase 1 PK/PD Study n=24 -16 -14 -12 -10 -8 -6 -4 -2 Time (min)
Slide 7: Phase 1 Pharmacokinetic (PK) comparison study (2007)
Phase 1 Pharmacokinetic (PK) comparison study (2007) Phase 1 Pharmacokinetic (PK) comparison study (2007)
Slide 8: Phase 1 PK comparison study design
: Phase 1 PK comparison study (2005) : Phase 1 PK comparison study (2005) Study design: Randomized, open-label, comparative, pharmacokinetic study of 3.5mg and Ambien 10mg in healthy adults Pharmacokinetic assessment: Blood was collected prior to dosing (T=0 minutes) and at 5, 10, 15, 20, 25, 30, 40
Slide 9: 3.5 mg vs. 10 mg Ambien plasma profile
Time (hours) 3.5 mg vs. mg Ambien plasma profile 3.5 mg vs. mg Ambien plasma profile 3.5mg vs. Ambien 10mg PO after an overnight fasting, n=33 3.5 mg Ambien 10 mg
Slide 10: 3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien dose
3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien dose 3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien dose 3.5mg vs. Ambien 10mg PO after an overnight fasting, n=33 9.3x 2.9x 1.4x 3.5 mg Ambien 10 mg Time (min)
Slide 11: Intermezzo Phase 3 clinical results
Intermezzo ® Phase 3 clinical results Phase 3 clinical results Low dose zolpidem for middle of the night (MOTN) insomnia
Slide 12: Phase 3 sleep lab study (2006)
: Phase 3 sleep lab study (2006) : Phase 3 sleep lab study (2006) Principal investigators: Thomas Roth, PhD and Martin Scharf, PhD Study design: Double-blind, placebo-controlled study for objective (PSG) evaluation of sleep-onset safety and efficacy of 1.75 mg and 3.5 mg after scheduled MOTN awakeni
Slide 13: Objective Latency to Persistent Sleep following a middle of the night awakening
37.29 23.71 14.16 44.64 30.66 16.97 Placebo Intermezzo® 1.75 mg Intermezzo® 3.5 mg : Objective Latency to Persistent Sleep following a middle of the night awakening : Objective Latency to Persistent Sleep following a middle of the night awakening Phase 3 Sleep Lab Study n = 82 1.75mg p<0.001 vs. Pla
Slide 14: Proportion of patients asleep following a middle of the night awakening
: proportion of patients asleep following a middle of the night awakening : proportion of patients asleep following a middle of the night awakening 75% 56% 28% Phase 3 Sleep Lab Study n = 82
Slide 15: Next-day residual effects of Intermezzo 1.75 mg and 3.5 mg vs. placebo
61.88 61.59 60.57 Placebo Intermezzo® 1.75 mg Intermezzo® 3.5 mg 62.35 64.25 63.56 Next-day residual effects of Intermezzo 1.75 mg and 3.5 mg vs. placebo Next-day residual effects of Intermezzo 1.75 mg and 3.5 mg vs. placebo Phase 3 Sleep Lab Study n = 82 Objective (DSST) 1.75mg p<0.62 vs. Placebo p
Slide 16: Good or Excellent next day ratings
23.5 32.9 42.6 23.5 36.5 40.0 39.5 47.6 51.3 Placebo Intermezzo® 1.75 mg Intermezzo® 3.5 mg : “Good” or “Excellent” next day ratings : “Good” or “Excellent” next day ratings Phase 3 Sleep Lab Study n = 82 Sleep Quality Refreshing Sleep Ability to Function 1.75mg NS p<0.017 vs. Placebo p<0.001 vs. Pl
Slide 17: Phase 3 outpatient study (2008)
Principal investigators: Andrew Krystal, MD and Thomas Roth, PhD Study design: Randomized, double-blind, placebo controlled, outpatient study to evaluate the safety and efficacy of 3.5 mg for the prn treatment of insomnia after MOTN awakening Study population: 294 non-elderly primary insomnia patien
Slide 18: Latency to Sleep Onset, 4 week average
69.42 56.37 68.13 38.22 Baseline : Latency to Sleep Onset, 4 week avg : Latency to Sleep Onset, 4 week avg Phase 3 outpatient study n = 294 p<0.0001 vs. Placebo 3.5mg Placebo Baseline 4 week treatment Baseline 4 week treatment Baseline
Slide 19: Latency to Sleep Onset, weekly
Placebo Intermezzo® 3.5 mg : Latency to Sleep Onset, weekly : Latency to Sleep Onset, weekly Phase 3 outpatient study n = 294 Baseline week 1 week 2 week 3 week 4 3.5mg Placebo p<0.0001 vs. Placebo p<0.0001 vs. Placebo p<0.0001 vs. Placebo p<0.0001 vs. Placebo
Slide 20: Next day sleepiness/alertness scores, 4 week average
4.71 5.24 4.87 5.59 Baseline : next day sleepiness/alertness scores, 4 week avg : next day sleepiness/alertness scores, 4 week avg Phase 3 outpatient study n = 294 p<0.0041 vs. Placebo 3.5mg Placebo Baseline 4 week treatment Baseline 4 week treatment Baseline MORE ALERT MORE SLEEPY
Slide 21: Average weekly treatment exposure
Placebo Intermezzo® 3.5 mg : average weekly treatment exposure : average weekly treatment exposure Placebo wk 1 Placebo wk 2 week 1 week 2 week 3 week 4 3.5mg Placebo Phase 3 outpatient study n = 294
Slide 22: Distribution of self-reported MOTN awakenings
Distribution of self-reported MOTN awakenings Distribution of self-reported MOTN awakenings Phase 3 outpatient study n = 294 MOTN treatment call to IVRS 8-9pm 9-10pm - 11pm - 12am 12-1am 1-2am 2-3am 3-4am 4-5am 5-6am 6-7am
Slide 23: Trademark of Transcept Pharmaceuticals, Inc.
is a trademark of Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals — Technical Presentation (April 2010) on 6ix